GLP1R and type 2 diabetes mellitus: Lixisenatide is a new selective once-daily GLP-1 receptor agonist that was approved by the European Medicines Agency in 2013 for the treatment of type 2 diabetes for the treatment of type 2 diabetes 9,13,23–28.